On January 30, 2015 the FDA approved a new indication for lisdexamfetamine (Vyvanse, Shire Pharmaceuticals): binge-eating disorder in adults. The drug is the first FDA-approved medication to treat this condition. Lisdexamfetamine is a combination of dexamphetamine bound to lysine. Conversion of lisdexamphetamine to the active metabolite d-amphetamine occurs primarily in the blood through enzymatic cleavage after active absorption of LDX from the GI lumen [1] . Lixexamfetamine for binge eating disorder, in brief [2] :
- Pivotal trials: two, 724 adults with moderate-to-severe binge-eating disorder
- Dosing range for binge eating disorder: 50–70 mg/day
- Primary endpoint: reductions in binge eating days/week
- Common adverse effects (incidence = 10% and greater than the rate for placebo): dry mouth, decreased appetite, insomnia and headache
References
- Goodman, David W. “Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.” Pharmacy and Therapeutics 35.5 (2010): 273. ↩
- Citrome, L. “Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.” International Journal of Clinical Practice (2015). ↩
